For this year’s Targeted Therapies Forum, Dr. Narjust Florez, Associate Director, Cancer Care Equity Program, Dana-Farber Cancer Institute; Assistant Professor of Medicine, Harvard Medical School; Thoracic Oncologist, Lowe Center for Thoracic Oncology, Dana Farber Cancer Insititute, discusses the Management of Oligoprogression in Mutated Advanced NSCLC.
In this video, Dr. Narjust Florez explains what defines oligoprogression of disease.
For more, please visit http://cancerGRACE.org/.
To join the conversation, visit https://cancergrace.org/forum.